Hanada Norihisa, Kawata Kousei, Okamura Shigeki, Tomiyama Nariaki, Hori Kazuki
Dept. of Surgery, Izumi General Medical Center, Japan.
Gan To Kagaku Ryoho. 2013 Jun;40(6):803-5.
Case 1: Recurrent tumors from gastric GIST in the liver and the abdominal wall showed partial response with 200mg/day imatinib and maintained partial response at 100mg/day. Case 2: Metastatic liver tumors from the jejunal GIST showed partial response with 200mg/day imatinib. The tumors have been enlarged for interruption of imatinib administration, however, re- treatment with imatinib resulted in partial response again and kept partial response at 100mg/day of imatinib. The two cases seldom encountered adverse events at 100mg/day of imatinib. There are some cases successfully treated with low-dose imatinib mesylate for recurrent GIST.
病例1：胃间质瘤肝转移及腹壁复发肿瘤患者，接受每日200mg伊马替尼治疗后出现部分缓解，每日100mg维持部分缓解。病例2：空肠间质瘤肝转移患者，接受每日200mg伊马替尼治疗后出现部分缓解。因中断伊马替尼治疗肿瘤增大，再次使用伊马替尼治疗后又出现部分缓解，每日100mg维持部分缓解。两例患者在每日100mg伊马替尼治疗时很少出现不良事件。有一些复发性胃肠道间质瘤病例采用低剂量甲磺酸伊马替尼治疗获得成功。
